logo
Sign in

TLX Stock Price, Chart, Stats & News

Telix Pharmaceuticals Limited
Save
3.68B
Market cap
Current P/E
2000.00x
Forward P/E

TLX chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
50.74%
Operating margin
2.11%
Pretax margin
-0.66%
Net margin
-0.88%
Effective tax rate
-131.02%
ROA
-0.61%
ROE
-2.06%
D/E
1.26x
Interest coverage ratio
1.64x

TLX valuation

P/E
P/S
3.73x
P/B
7.28x
P/CF
-177.15x
P/FCF
-59.82x
P/OCF
-177.15x
PEG
2.25x
EV multiple
104.68x

About

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.

Similar securities

Based on sector and market capitalization

Report issue